Quinolone Resistance Due to Reduced Target Enzyme Expression
Open Access
- 1 December 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 185 (23) , 6883-6892
- https://doi.org/10.1128/jb.185.23.6883-6892.2003
Abstract
We report for the first time low-level quinolone resistance mediated by decreased expression of topoisomerase IV in Staphylococcus aureus . A single-step mutant of wild-type S. aureus strain ISP794, P18 selected by using twice the MIC of premafloxacin, had four- and four- to eightfold greater MICs of premafloxacin and ciprofloxacin, respectively, than the wild type. Sequencing of parEC and gyrBA with their promoter regions revealed a point mutation (G→A) 13 bp upstream of the start codon of parE . Genetic linkage studies showed that there was a high level of correlation between the mutation and the resistance phenotype, and allelic exchange confirmed the contribution of the mutation to resistance. Decreased expression of ParE and decreased steady-state levels of parEC transcripts in P18 and in resistant allelic exchange mutants were observed. The steady-state levels of gyrBA and topB transcripts were increased in P18 but not in two resistant allelic exchange mutants, and sequencing upstream of either gene did not reveal a difference between ISP794 and P18. The steady-state levels of topA transcripts were similar in the various strains. Growth competition experiments performed at 30, 37, and 41°C with a susceptible allelic exchange strain and a resistant allelic exchange strain suggested that loss of fitness was associated with reduced levels of ParE at 41°C. However, P18 had a growth advantage over ISP794 at all temperatures, suggesting that a compensatory mechanism was associated with the increased levels of gyrBA and topB transcripts. Thus, reduced levels of ParE appear to be compatible with cell survival, although there may be a fitness cost during rapid cell multiplication, which might be overcome by compensatory mechanisms without reversion of the resistance phenotype.Keywords
This publication has 65 references indexed in Scilit:
- Topoisomerase III Can Serve as the Cellular Decatenase in Escherichia coliPublished by Elsevier ,2003
- Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003
- The Glu-84 of the ParC Subunit Plays Critical Roles in Both Topoisomerase IV−Quinolone and Topoisomerase IV−DNA InteractionsBiochemistry, 2002
- gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivityJournal of Molecular Biology, 2001
- Mechanisms of fluoroquinolone resistanceDrug Resistance Updates, 1999
- Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant Gram-positive human pathogensJournal of Antimicrobial Chemotherapy, 1996
- Transcription and DNA supercoilingCurrent Opinion in Genetics & Development, 1993
- The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replicationCell, 1992
- Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolonesMutagenesis, 1990
- The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophageNature, 1983